Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox

Few large pharmaceutical companies have had to rebuild their revenue base as publicly as AbbVie. When the company was spun out of Abbott Laboratories in 2013, it was essentially one drug wearing a corporate structure: Humira, the anti-inflammatory antibody that became the best-selling medicine in the world. Any serious AbbVie stock analysis now has to start from the fact that Humira is no longer the story. In the second quarter of 2026, reported 31 July 2026, Humira contributed $756 million of a $16.99 billion revenue quarter, having fallen 36.1% on an operational basis. The company grew total net revenues 10.2% anyway. Understanding how that arithmetic works is the core of understanding AbbVie today.

How AbbVie Makes Its Money

AbbVie reports through four commercial portfolios, and they behave very differently from one another.

• Immunology is the engine. The portfolio delivered $8.79 billion in Q2 2026. Two products account for roughly 91% of it: Skyrizi (risankizumab), an IL-23 inhibitor used in psoriasis, psoriatic arthritis and inflammatory bowel disease, and Rinvoq (upadacitinib), an oral JAK inhibitor with a widening list of approved indications.
• Neuroscience is the fastest-growing of the rest, at $3.228 billion in the quarter, up 20.3% as reported. It is built on Vraylar in psychiatry ($1.071 billion), Botox Therapeutic for chronic migraine and spasticity ($1.042 billion), and the migraine pair Ubrelvy and Qulipta ($742 million combined).
• Oncology generated $1.650 billion, down 1.5% as reported. Venclexta in blood cancers was the largest contributor at $771 million, while Elahere, the ovarian cancer antibody-drug conjugate acquired with ImmunoGen, grew 33.1% to $211 million.
• Aesthetics is the cyclical outlier, at $1.282 billion, essentially flat on a reported basis and down 0.9% operationally. Botox Cosmetic rose 5.2% to $728 million while Juvederm dermal fillers fell 6.0% to $245 million.

That mix matters for how an investor reads the business. Immunology and neuroscience are prescription franchises whose demand is driven by diagnosis rates, guidelines and reimbursement. Aesthetics is a consumer business in medical clothing: patients pay out of pocket, so it flexes with discretionary spending in a way that a Crohn's disease therapy does not. When AbbVie's overall growth rate wobbles, aesthetics is often the reason, and it is worth separating that from what is happening in the drug portfolios.

The Humira Transition and What Replaced It

Humira lost US exclusivity in 2023, when Amgen (AMGN) launched the first American biosimilar and others followed. Biosimilar erosion of a product that once generated more than $20 billion a year is the single largest event in AbbVie's history as an independent company, and the Q2 2026 figure of $756 million shows how far that decline has run.

What makes the AbbVie stock analysis unusual is that the replacement was engineered in advance. Skyrizi and Rinvoq were developed and launched while Humira was still at peak, and by Q2 2026 they were generating roughly $8.03 billion between them in a single quarter, comfortably more than Humira's best quarters. Skyrizi alone reached about $5.5 billion, up around 24% operationally, and Rinvoq passed $2.5 billion, up 23.7%. Both products are still adding indications rather than defending mature ones.

The exclusivity runway is the other half of the picture. Core US composition-of-matter patents for both drugs were originally expected to expire in 2033. AbbVie has since settled with the generic filers challenging Rinvoq, including Sandoz, Hetero Labs, Aurobindo, Intas and Sun Pharmaceuticals, in agreements that keep US generic upadacitinib off the market until April 2037. That does not eliminate patent risk, but it changes the shape of it: the next cliff is a decade out rather than imminent, which is a materially different planning horizon from the one AbbVie faced in 2021.

Competition inside the exclusivity period is a separate matter. Johnson & Johnson (JNJ) competes directly in psoriasis and inflammatory bowel disease, and the immunology market has become a contest of head-to-head trial data and payer contracting rather than a race for first approval.

Margins, Cash Flow and the Dividend

Branded pharmaceuticals are a high-gross-margin business, and AbbVie is no exception. In Q2 2026 the adjusted gross margin was 84.7% of sales, research and development ran at 13.6% of sales, and the adjusted operating margin was 48.3%, a figure that itself absorbed a 1.7 percentage point unfavorable impact from acquired in-process R&D expense.

That last point is worth pausing on, because it explains a recurring gap between AbbVie's two earnings numbers. GAAP diluted earnings per share for the quarter were $2.03. Adjusted diluted EPS were $3.65, up 22.9% year on year. The difference comes largely from intangible amortization on past acquisitions and from acquired IPR&D and milestone charges, which cost $0.17 per share in the quarter alone. Neither number is the real one: GAAP captures the full accounting cost of a company built partly by acquisition, while the adjusted figure is closer to the underlying cash economics of selling the drugs. An investor reading AbbVie needs to know which is being quoted.

The dividend is central to how this stock is owned. AbbVie declared a quarterly dividend of $1.73 per share in June 2026, payable 14 August 2026, which annualizes to $6.92. Against a closing share price of $249.46 on 14 August 2026, that is a yield of about 2.8%. The company has raised the payout by more than 330% since its 2013 inception and sits in the S&P Dividend Aristocrats index. The relevant question for a dividend investor is not the headline yield but the durability of the cash flow behind it, which now depends on Skyrizi and Rinvoq rather than Humira.

The balance sheet remains the counterweight. AbbVie carries substantial debt, much of it originating with the 2020 acquisition of Allergan, and management has consistently framed deleveraging as competing with buybacks for capital. Any assessment of dividend capacity should be read alongside that debt load rather than in isolation.

Growth Investment: Apogee and the Pipeline

AbbVie has continued to buy growth. In June 2026 it agreed to acquire Apogee Therapeutics for $135.11 per share in cash, an equity value of roughly $10.9 billion, with completion expected in the third quarter of 2026. Apogee is a clinical-stage biotech whose lead asset, zumilokibart, is an extended half-life IL-13 antibody aimed at atopic dermatitis and other inflammatory conditions. The strategic logic is straightforward: deepen the immunology franchise that already produces close to half of company revenue, and do it with a molecule designed for less frequent dosing than incumbents.

The near-term financial effect was visible in guidance. Alongside Q2 results, AbbVie raised full-year 2026 revenue guidance by about $300 million to approximately $67.6 billion, while trimming adjusted diluted EPS guidance to $13.87 to $14.07 from $13.91 to $14.11 specifically to reflect anticipated dilution from the Apogee transaction. That combination, revenue up and adjusted EPS down slightly, is a useful illustration of how deal accounting can pull the two lines in opposite directions.

Beyond Apogee, management has pointed to several regulatory catalysts, including a subcutaneous induction option for Skyrizi in Crohn's disease and potential Rinvoq approvals in vitiligo and alopecia areata. Each incremental indication matters more than it might appear, because indication expansion is how a drug with fixed patent life grows into a larger addressable population.

What the Valuation Multiples Read Today

Valuation for AbbVie requires care precisely because of the GAAP versus adjusted gap described above. Trailing P/E ratios calculated on GAAP earnings screen very high, and readings differ widely between data providers depending on which earnings figure and which period they use. That dispersion is a data artifact of heavy amortization and IPR&D charges, not a signal in itself.

On the company's own guidance, the arithmetic is more stable. The $249.46 close on 14 August 2026 against the midpoint of the FY2026 adjusted diluted EPS range of $13.87 to $14.07 works out at roughly 17.9 times guided adjusted earnings. Market capitalization was around $443 billion in August 2026. A price-to-earnings multiple simply expresses what the market is currently paying for a dollar of earnings; it says nothing on its own about whether those earnings will persist, which for a patent-based business is the whole question.

The more informative exercise is to ask what the multiple implies about the durability of Skyrizi and Rinvoq revenue through the early 2030s, since those two products underwrite most of the earnings base being capitalized.

Risks and What to Watch

Several specific factors would change the picture rather than merely move the share price for a week.

• Concentration. Two products generate close to half of company revenue. A safety signal, a reimbursement setback or a competitive trial result affecting Skyrizi or Rinvoq would matter disproportionately.
• JAK class labeling. Rinvoq belongs to a drug class carrying boxed warnings covering serious infection, mortality, malignancy and thrombosis risk, following cardiovascular safety findings associated with Pfizer's (PFE) tofacitinib. Prescriber caution within the class is a structural constraint on how broadly oral JAK inhibitors are used.
• US drug pricing policy. Medicare negotiation and broader pricing reform apply to exactly the kind of high-revenue branded products AbbVie sells. This is a policy variable, not a company-controlled one.
• Aesthetics demand. Botox Cosmetic and Juvederm are consumer-funded and have been close to flat. Sustained softness here would drag on group growth even with immunology performing.
• Deal execution and leverage. Apogee's lead asset is still clinical-stage. AbbVie has a strong record of integrating acquisitions, but $10.9 billion committed to an unapproved molecule is capital at risk, and it sits on top of an already leveraged balance sheet.

The counterweights are equally concrete: 84.7% adjusted gross margins, immunology exclusivity extended toward 2037 for Rinvoq, a still-expanding indication list, and a dividend supported by a franchise that is growing rather than eroding. The same set of questions, patent runway, pipeline replacement and dividend cover, shapes the reading of GlaxoSmithKline (GSK), where vaccines carry more of the load, and of Eli Lilly (LLY), whose growth rests on an entirely different therapeutic franchise.

Conclusion: What the Numbers Show

This AbbVie stock analysis describes a company that has already completed the transition most investors were worried about. The Humira cliff arrived, revenue from that product fell by more than a third year on year in Q2 2026, and the company still grew total net revenues 10.2% to $16.99 billion because Skyrizi and Rinvoq more than filled the gap. Margins remain characteristic of branded pharmaceuticals, the dividend has been raised consistently since 2013, and management is redeploying cash into the same therapeutic area that is working.

What to watch from here is narrower than it used to be. The key variables are the growth rate of Skyrizi and Rinvoq as they mature, whether new indications keep landing, how the Apogee acquisition converts spending into an approved product, the pace of debt reduction, and whether aesthetics stabilizes. Each of those is observable in the quarterly reporting, which makes AbbVie a business an investor can track on evidence rather than on narrative, provided the GAAP and adjusted figures are never confused for one another.